CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+18.02%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
-$12.1M
(-1.1%)
Cap. Flow
-$153M
Cap. Flow
% of AUM
-14.42%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
262
Reduced
172
Closed
24
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
+$6.59M |
| 2 |
iShares Gold Trust Micro
IAUM
|
+$4.62M |
| 3 |
Intuit
INTU
|
+$3.73M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
+$3.6M |
| 5 |
T-Mobile US
TMUS
|
+$2.35M |
Top Sells
| 1 |
Apple
AAPL
|
+$17.4M |
| 2 |
NVIDIA
NVDA
|
+$12.2M |
| 3 |
Microsoft
MSFT
|
+$11.5M |
| 4 |
Amazon
AMZN
|
+$8.86M |
| 5 |
Broadcom
AVGO
|
+$8.43M |
Sector Composition
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
451
C4 Therapeutics
CCCC
$187M
| $20.4K | ﹤0.01% |
14,261
+22
| +0.2% | +$31 |
|
452
Edwards Lifesciences
EW
$46B
| $20K | ﹤0.01% |
256
| – | – |
|
|
CLYM
453
Climb Bio, Inc. Common Stock
CLYM
$162M
| $16.8K | ﹤0.01% |
13,572
+88
| +0.7% | +$109 |
|
454
MacroGenics
MGNX
$109M
| $15.3K | ﹤0.01% |
12,671
+82
| +0.7% | +$99 |
|
455
TScan Therapeutics
TCRX
$104M
| $15.2K | ﹤0.01% |
10,507
+660
| +7% | +$957 |
|
456
Repligen
RGEN
$6.77B
| $14.3K | ﹤0.01% |
115
| – | – |
|
457
Pliant Therapeutics
PLRX
$104M
| $14.3K | ﹤0.01% |
12,329
+123
| +1% | +$143 |
|
458
Illumina
ILMN
$14.7B
| $13.9K | ﹤0.01% |
146
| – | – |
|
459
Pyxis Oncology
PYXS
$116M
| $13.7K | ﹤0.01% |
12,442
+514
| +4% | +$565 |
|
460
Biomea Fusion
BMEA
$110M
| $13.6K | ﹤0.01% |
7,546
+277
| +4% | +$499 |
|
461
Charles River Laboratories
CRL
$7.54B
| $13.5K | ﹤0.01% |
89
| – | – |
|
462
GSK
GSK
$81.5B
| $13.1K | ﹤0.01% |
338
| – | – |
|
463
Quanterix
QTRX
$201M
| $12.6K | ﹤0.01% |
1,894
| – | – |
|
464
Sutro Biopharma
STRO
$76.5M
| $12.1K | ﹤0.01% |
16,964
+424
| +3% | +$303 |
|
465
SPDR S&P Dividend ETF
SDY
$20.3B
| $10.2K | ﹤0.01% |
75
| – | – |
|
466
Applied Therapeutics
APLT
$64.1M
| $8.85K | ﹤0.01% |
28,435
+5,096
| +22% | +$1.59K |
|
|
IGMS
467
DELISTED
IGM Biosciences
IGMS
| $7.81K | ﹤0.01% |
6,975
+140
| +2% | +$157 |
|
468
Acrivon Therapeutics
ACRV
$51.6M
| $7.5K | ﹤0.01% |
6,298
+53
| +0.8% | +$63 |
|
469
Mersana Therapeutics
MRSN
$36.9M
| $7.41K | ﹤0.01% |
1,001
+10
| +1% | +$74 |
|
|
ARTV
470
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$65.9M
| $7.39K | ﹤0.01% |
4,893
+21
| +0.4% | +$32 |
|
471
PepGen
PEPG
$45.9M
| $7.3K | ﹤0.01% |
6,572
+14
| +0.2% | +$16 |
|
|
OKUR
472
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$33.6M
| $6.16K | ﹤0.01% |
2,576
+38
| +1% | +$91 |
|
473
Wolfspeed
WOLF
$230M
| $3.99K | ﹤0.01% |
10,000
| – | – |
|
474
Q32 Bio
QTTB
$21.6M
| $3.65K | ﹤0.01% |
2,450
+7
| +0.3% | +$10 |
|
475
Hershey
HSY
$37.6B
| $1.66K | ﹤0.01% |
10
| – | – |
|